How far are we in understanding the cause of Parkinson's disease?

Journal of Neurology Neurosurgery and Psychiatry

Volumn 61, Issue 1, 1996, Pages 4-16

  Ben Shlomo, Y ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; WELL WATER;

DIET; DISEASE CLASSIFICATION; ENVIRONMENTAL EXPOSURE; GEOGRAPHIC DISTRIBUTION; HEAD INJURY; HUMAN; INFECTION; MORTALITY; PARKINSON DISEASE; PERSONALITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RURAL POPULATION; SMOKING; SOCIAL CLASS;

EID: 0030054732     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.61.1.4     Document Type: Review

References (165)

1. Parkinson J. An essay on the shaking palsy. London: Sherwood, Neely, and Jones, 1817:1-66
2. Koller WC, Wong GF, Lang A. Posttraumatic movement disorders: a review. Mov Disord 1989;4:20-36.
3. Factor SA, Sanchez Ramos J, Weiner WJ. Trauma as an etiology of parkinsonism: a historical review of the concept. Mov Disord 1988;3:30-6.
4. Stern MB. Head trauma as a risk factor for Parkinson's disease. Mov Disord 1991;6:95-7.
5. Khoury MJ, Beaty TH, Cohen BH. Fundamentals of genetic epidemiology. New York: Oxford University Press, 1993: 3-383
6. Sasco AJ, Paffenbarger RS. Measles infection and Parkinson's disease. Am J Epidemiol 1985;122:1017-31.
7. Ben-Shlomo Y, Sieradzan K. Idiopathic parkinson's disease: epidemiology, diagnosis and management. Br J Gen Pract 1995;45:261-8.
8. Mutch WJ, Dingwall-Fordyce I, Downie AW, Paterson JG, Roy SK. Parkinson's disease in a Scottish city. BMJ 1986;292:534-6.
9. Harada H, Nishikawa S, Takahashi K. Epidemiology of Parkinson's disease in a Japanese city. Arch Neurol 1983; 40:151-4.
10. Martilla RJ, Rinne UK. Epidemiology of Parkinson's disease in Finland. Acta Neurol Scand 1976;53:81-102.
11. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathologjcal study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
12. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathological study. Neurology 1992;42:1142-6.
13. Riggs JE. Smoking and Alzheimer's disease: protective effect or differential survival bias? Lancet 1993;342: 793-4.
14. Mattock C, Marmot M, Stern G. Could Parkinson's disease follow intra-uterine influenza?: a speculative hypothesis. J Neurol Neurosurg Psychiatry 1988;51:753-6.
15. Eldridge R, Ince SE. The low concordance rate for Parkinson's disease in twins: a possible explanation. Neurology 1984;34:1354-6.
16. Calne DB, Langston JW. Aetiology of Parkinson's disease. Lancet 1983;2:1457-9.
17. Langston JW. Predicting Parkinson's disease. Neurology 1990;40:70-4.
18. Koller WC, Langston JW, Hubble JP, et al. Does a long preclinical period occur in Parkinson's disease?. Neurology 1991;41:8-13.
19. Koller WC. When does Parkinson's disease begin? Neurology 1992;42 (suppl 4):27-31.
20. Gibb WR, Lees AJ. The progression of idiopathic Parkinson's disease is not explained by age-related changes. Clinical and pathological comparisons with post-encephalitic parkinsonian syndrome. Acta Neuropathol (Berl) 1987;73:195-201.
21. Schulzer M, Lee CS, Mak EK, Vingerhoets JG, Calne DB. A mathematical model of pathogenesis in idiopathic parkinsonism. Brain 1994;117:509-16.
22. Goldberg ID, Kurland LT. Mortality in 33 countries from diseases of the nervous system. World Neurology 1962; 3:444-63.
23. Williams GR. Morbidity and mortality with parkinsonism. J Neurosurg 1966;24 (suppl):138-43.
24. Zhang Z, Roman GC. Worldwide occurence of Parkinson's disease: an updated review. Neuroepidemiology 1993;12:195-208.
25. Hayward RA, Shapiro MF, Freeman HE, Corey CR. Inequities in health services among insured Americans. N Engl J Med 1988;318:1507-12.
26. Schoenberg BS, Anderson DW, Haerer AF. Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi. Neurology 1985;35:841-5.
27. de Pedro-Cuesta J. Parkinson's disease diagnostic criteria, incidence and etiology: III Europarkinson Workshop. Madrid: Institute of Health, 1991.
28. Wang SJ, Fuh JL, Liu CY, et al. Parkinson's disease in Kin-Hu, Kinmen: a community survey by neurologists. Neuroepidemiobgy 1994;13:69-74.
29. Jendroska K, Olasode BJ, Daniel SE, et al. Incidental Lewy body disease in black Africans. Lancet 1994;344:882-3.
30. Ben-Shlomo Y, Wenning G. Incidental Lewy body disease. Lancet 1994;344:1503.
31. Tanner CM, Chen B, Wang W, et al. Environmental factors and Parkinson's disease: a case-control study in China. Neurology 1989;39:660-4.
32. Marmot MG, Adelstein AM, Bulusu L. Lessons from the study of immigrant mortality. Lancet 1984;i:1455-8.
33. Gudmundsson KR. A clinical survey of Parkinsonism in Iceland. Acta Neurol Scand 1967;43 (suppl 33):9-61.
34. de Pedro-Cuesta J, Petersen IJ, Stawiarz L, et al. High levodopa use in periodically time-clustered, Icelandic birth cohorts. A vestige of parkinsonism etiology? Acta Neurol Scand 1995;91:79-88.
35. Manyam BV. Paralysis agitans and levodopa in "Ayurveda": ancient Indian medical treatise. Mov Disord 1990;5:47-8.
36. Kurtzke JF, Murphy FM. The changing patterns of death rates in parkinsonism. Neurology 1990;40:42-9.
37. Treves TA, de Pedro-Cuesta J. Parkinsonism mortality in the US, 1. Time and space distribution. Acta Neurol Scand 1991;84:389-97.
38. Lilienfeld DE, Chan E, Ehland J, et al. Two decades of increasing mortality from Parkinson's disease among the US elderly. Arch Neurol 1990;47:731-4.
39. Duvoisin RC, Schweitzer MD. Paralysis agitans mortality in England and Wales, 1855-1962. Br J Prev Soc Med 1966;20:27-33.
40. Marmot MG. Parkinson's disease and encephalitis: the cohort hypothesis re-examined. In: Rose FC, ed. Clinical neuroepidemiology. Kent: Pitman Medical, 1980; 391-401.
41. Li T, Swash M, Alberman E. Morbidity and mortality in motor neuron disease: comparison with multiple sclerosis and Parkinson's disease: age and sex specific rates and cohort analyses. J Neurol Neurosurg Psychiatry 1985;48: 320-7.
42. Clarke CE. Mortality from Parkinson's disease in England and Wales 1921-1989. J Neurol Neurosurg Psychiatry 1993;56:690-3.
43. Ben-Shlomo Y, Finnan F, Allwright S, Davey Smith G. The epidemiology of Parkinson's disease in Ireland: observations from routine data sources. Ir Med J 1993;86:190-4.
44. Vanacore N, Bonifati V, Bellatreccia A, Edito F, Meco G. Mortality rates for Parkinson's disease and parkinsonism in Italy (1969-1987). Neuroepidemiology 1992;11:65-73.
45. Kurtzke JF, Flaten TP, Murphy FM. Death rates from Parkinson's disease in Norway reflect increased survival. Neurology 1991;41:1665-7.
46. Imaizumi Y, Kaneko R. Rising mortality from Parkinson's disease in Japan, 1950-1992. Acta Neurol Scand 1995; 91:169-76.
47. Clarke CE. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence. Mov Disord 1995;10:250-6.
48. Ebmeier KP, Calder SA, Crawford JR, Stewart L, Beeson JAO, Mutch WJ. Parkinson's disease in Aberdeen: survival after 3-5 years. Acta Neurol Scand 1990;81:294-9.
49. Ben-Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology. J Neurol Neurosurg Psychiatry 1995;58:293-9.
50. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-42.
51. Riggs JE, Schochet SS. Rising mortality due to Parkinson's disease and amyotrophic lateral sclerosis: a manifestation of the competitive nature of human mortality. J Clin Epidemiol 1992;45:1007-12.
52. Bennett DA, Beckert LA, Murray AM, et al. Prevalence of Parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996; 334:71-6.
53. Poskanzer DC, Schwab RS. Cohort analysis of Parkinson's syndrome. Evidence for a single etiology related to subclinical infection about 1920. J Chron Dis 1963;16: 961-73.
54. Brown EL, Knox EG. Epidemiological approach to Parkinson's disease. Lancet 1972;1:974-6.
55. Holford TR. Analysing the temporal effects of age, period and cohort. Statistical Methods in Medical Research 1992;1:317-37.
56. Ravenholt RT, Foege WH. 1918 Influenza, encephalitis lethargica, parkinsonism. Lancet 1982;ii:860-4.
57. Kurland LT, Hauser WA, Okazaki H, Nobrega FT. Epidemiologic studies of Parkinsonism with special reference to the cohort hypothesis. In: Proceedings of the third symposium on Parkinsonism. Edinburgh: Livingstone, 1969:12-6.
58. Nobrega FT, Glattre E, Kurland LT, Okazaki H. Comments on the epidemiology of parkinsonism including prevalence and incidence statistics for Rochester, Minnesota, 1953-1966. In: Barbeau A, Brunette JR, eds. Progress in Neurogenetics. Amsterdam: Excerpta Medica, 1969:474-85.
59. Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification and mortality. Ann Neurol 1984;16:278-82.
60. de Pedro-Cuesta J, Stawiarz L. Parkinson's disease incidence: magnitude, comparability, time trends. Acta Neurol Scand 1991;84:382-8.
61. Ritchie K, Kildea D. Is senile dementia "age-related" or ageing-related"? - evidence from meta-analysis of dementia prevalence in the oldest old. Lancet 1995;346: 931-4.
62. Larsen JP and the Norwegian Study Group of Parkinson's disease in the elderly. Parkinson's disease as community health problem: study in Norwegian nursing homes. BMJ 1991;303:741-3.
63. Li S, Schoenberg BS, Wang C, et al. A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch Neurol 1985;42: 655-7.
64. Morgante L, Rocca WA, Di Rosa AE, et al. Prevalence of Parkinson's disease and other types of parkinsonism: a door-to-door survey in three Sicillian municipalities. Neurology 1992;42:1901-7.
65. Bharucha NE, Bharucha EP, Bharucha AE, Bhise AV, Schoenberg BS. Prevalence of Parkinson's disease in the Parsi community of Bombay, India. Arch Neurol 1988; 45:1321-3.
66. Tison F, Dartigues JF, Dubes L, Zuber M, Alperovitch A, Henry P. Prevalence of Parkinson's disease in the elderly: a population study in Gironde, France. Acta Neurol Scand 1994;90:111-5.
67. Liberatos P, Link BG, Kelsey JL. The measurement of social class in epidemiology. Epidemiol Rev 1988;10: 87-121.
68. Marmot MG, Shipley MJ, Rose G. Inequalities in death - specific explanations of a general pattern? Lancet 1984;i:1003-6.
69. Office of Population Census and Surveys. Classification of occupations. London: HMSO, 1980
70. McKeigue PM, Marmot MG. Epidemiology of Parkinson's disease. In: Stern G, ed. Parkinson's disease. London: Chapman and Hall, 1989:295-306.
71. Breslow NE, Day NE. Statistical methods in cancer research: Volume 2 - the design and analysis of cohort studies. Lyon: IARC:1987.
72. Kessler II. Epidemiologic studies of Parkinson's disease. III. A community based survey. Am J Epidemiol 1972; 96:242-54.
73. Martilla RJ, Rinne UK. Arteriosclerosis, hereditary and some previous infections in the aetiology of Parkinson's disease. A case control study. Clin Neurol Neurosurg 1976;79:46-56.
74. Stern M, Dulaney E, Gruber SB, et al. The epidemiology of Parkinson's disease: a case-control study of young-onset and old-onset patients. Arch Neurol 1991;48: 903-7.
75. Semchuck KM, Love EJ, Lee RG. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 1992;42:1328-35.
76. Mayeux R, Tang MX, Marder K, Cote LJ, Stern Y. Smoking and Parkinson's disease. Mov Disord 1994;9: 207-12.
77. Butterfield PG, Valanis BG, Spencer PS, Lindeman CA, Nutt JG. Environmental antecedents of young-onset Parkinson's disease. Neurology 1993;43: 1150-8.
78. Bharucha NE, Stokes L, Schoenberg BS, et al. A case-control study of twin pairs discordant for Parkinson's disease: a search for environmental risk factors. Neurology 1986;36:284-8.
79. Grandinetti A, Morens DM, Reed D, MacEachern D. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol 1994;139:1129-38.
80. Ho SC, Woo J, Lee CM. Epidemiologic study of Parkinson's disease in Hong Kong. Neurology 1989;39: 1314-8.
81. Hubble JP, Cao T, Hassanein RE, Neuberger JS, Koller WC. Risk factors for Parkinson's disease. Neurology 1993;43:1693-7.
82. Wong GF, Gray CS, Hassanein RS, Koller WC. Environmental risk factors in siblings with Parkinson's disease. Arch Neurol 1991;48:287-9.
83. Koller W, Vetere-Overfield B, Gray C, et al. Environmental risk factors in Parkinson's disease. Neurology 1990;40:1218-21.
84. Barbeau A, Roy M, Bernier G, Campanella G, Paris S. Ecogenerics of Parkinson's disease: prevalence and environmental aspects in rural areas. Can J Neurol Sci 1987;14:36-41.
85. Golbe LI, Farrell TM, Davis PH. Follow-up study of early-life protective and risk factors in Parkinson's disease. Mov Disord 1990;5:66-70.
86. Ohlson C, Hogstedt C. Parkinson's disease and occupational exposure to organic solvents, agricultural chemicals and mercury - a case-referent study. Scand J Work Environ Health 1981;7:252-6.
87. Jimenez-Jimenez FJ, Mateo D, Gimenez-Roldan S. Exposure to well water and pesticides in Parkinson's disease: a case-control study in the Madrid area. Mov Disord 1992;7:149-52.
88. Ngim C, Devathasan G. Epidemiologic study on the association between body burden mercury level and idiopathic Parkinson's disease. Neuroepidemiology 1989;8: 128-41.
89. Aquilonius SM, Hartvig P. A Swedish county with unexpectedly high utilization of anti-parkinsonian drugs. Acta Neurol Scand 1986;74:379-82.
90. Wang WZ, Fang XH, Cheng XM, Jiang DH, Lin ZJ. A case-control study on the environmental risk factors of Parkinson's disease in Tianjin, China. Neuroepidemiology 1993;12:209-18.
91. Ebmeier KP, Mutch WJ, Calder SA, Crawford JR, Stewart L, Besson JO. Does idiopathic Parkinsonism in Aberdeen follow intrauterine influenza? J Neurol Neurosurg Psychiatry 1989;52:911-3.
92. Baumann RJ, Jameson HD, McKean HE, Haack DG, Weisberg LM. Cigarette smoking and Parkinson disease: 1. A comparison of cases with matched neighbours. Neurology 1980;30:839-43.
93. Godwin-Austen RB, Lee PN, Marmot MG, Stern GM. Smoking and Parkinson's disease. J Neurol Neurosurg Psychiatry 1982;45:577-81.
94. Kondo K. Epidemiological evaluations of risk factors in Parkinson's disease. Adv Neurol 1987;45:289-93.
95. Semchuk KM, Love EJ, Lee RG. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 1993;43:1173-80.
96. Nefzger MD, Quadfasel FA, Karl VC. A retrospective study of smoking in Parkinson's disease. Am J Epidemiol 1968;88:149-58.
97. Martilla RJ, Rinne UK. Smoking and Parkinson's disease. Acta Neurol Scand 1980;62:322-25.
98. Haack DG, Baumann RJ, McKean HE, Jameson HD, Turbek JA. Nicotine exposure and Parkinson disease. Am J Epidemiol 1981;114:191-9.
99. Rajput AH, Offord KP, Beard CM, Kurland LT. A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease. Neurology 1987;37:226-32.
100. Jimenez Jimenez FJ, Mateo D, Gimenez Roldan S. Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson's disease: a case-control study. Mov Disord 1992;7:339-44.
101. Kahn HA. The Dom study of smoking and mortality among U.S. Veterans: report on eight and one-half years of observation. Nat Cancer Inst Monogr 1966;19: 1-125.
102. Hammond EC. Smoking in relation to the death rates of one million men and women. In: Haenzel W, ed. Epidemiological approaches to the study of cancer and other chronic diseases. Bethesda, MD: National Cancer Institute, 1966:127-204. (National Cancer Institute Monograph No 19.)
103. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994;309:901-11.
104. Sasco AJ, Paffenbarger RSJ. Smoking and Parkinson's disease. Epidemiology 1990;1:460-5.
105. Poewe W, Karamat E, Kemmler GW, Gerstenbrand F. The premorbid personality of patients with Parkinson's disease: a comparative study with healthy controls and patients with essential tremor. Adv Neurol 1990;53: 339-12.
106. Eatough VM, Kempster PA, Stern GM, Lees AJ. Premorbid personality and idiopathic Parkinson's disease. Adv Neurol 1990;53:335-7.
107. Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983;33:815-24.
108. Williams DB, Annegers JF, Kokmen E, O'Brien PC, Kurland LT. Brain injury and neurologic sequelae: a cohort study of dementia, parkinsonism, and amyotrophic lateral sclerosis. Neurology 1991;41:1554-7.
109. Sernchuck KM, Love EJ, Lee RG. Parkinson's disease and exposure to rural environmental factors: a population based case-control study. Can J Neurol Sci 1991;18: 279-86.
110. Golbe LI, Farrell TM, Davis PH. Case-control study of early life dietary factors in Parkinson's disease. Arch Neurol 1988;45:1350-3.
111. Tanner CM, Chen B, Cohen JA, et al. Dietary antioxidant vitamins and the risk of developing Parkinson's disease. Neurology 1989;39:181
112. Cerhan JR, Wallace RB, Folsom AR. Antioxidant intake and risk of Parkinson's disease (PD) in older women. Am J Epidemiol 1994;139:S65.
113. Lang AE, Marsden CD, Obeso JA, Parkes JD. Alcohol and Parkinson disease. Ann Neurol 1982;12:254-6.
114. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:970-80.
115. Tanner CM, Langston JW. Do environmental toxins cause Parkinson's disease? A critical review. Neurology 1990; 40:suppl 30.
116. Sanchez-Ramos JR, Hefti F, Weiner WJ. Paraquat and Parkinson's disease. Neurology 1987;37:728.
117. Blair A, Zahm SH. Patterns of pesticide use among farmers: implications for epidemiologic research. Epidemiology 1993;4:55-62.
118. Stephens R, Spurgeon A, Calvert IA, et al. Neuropsychological effects of long-term exposure to organophosphates in sheep dip. Lancet 1995;345:1135-9.
119. Robins AH. Depression in patients with parkinsonism. Br J Psychiatry 1976;128:141-5.
120. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992;149:443-54.
121. Yesalis CEI, Lemke JH, Wallace RB, Kohonut FJ, Morris MC. Health status of the rural elderly according to farm work history: the Iowa 65+ rural health study. Arch Environ Health 1985;40:245-50.
122. Tanner C. Abnormal liver enzyme-mediated metabolism in Parkinson's disease: a second look. Neurology 1991;41:89-91.
123. Steventon GB, Heafield MTE, Waring RH, Williams AC. Xenobiotic metabolism in Parkinson's disease. Neurology 1989;39:883-7.
124. Steventon GB, Heafield MTE, Sturman SG, Waring RH, Williams AC, Ellingham J. Degenerative neurological disease and debrisoquine-4-hydroxylation capacity. Medical Science Research 1989;17:163-4.
125. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992;339:1017-8.
126. Smith CAD, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and suceptibility to Parkinson's disease. Lancet 1992;339:1375-7.
127. Agid Y. Parkinson's disease: pathophysiology. Lancet 1991;337:1321-3.
128. Elizan TS, Madden DL, Noble GR, et al. Viral antibodies in serum and CSF of parkinsonian patients and controls. Arch Neurol 1979;36:529-34.
129. Martilla RJ, Arstila P, Nikostelainen J, Halonen PE, Rinne UK. Viral antibodies in the sera from patients with Parkinson's disease. Eur Neurol 1977;15:25-33.
130. Schwartz J, Elizan TS. Search for viral particles and virus-specific products in idiopathic Parkinson disease brain material. Ann Neurol 1979;6:261-3.
131. Martyn CN, Cruddas M, Compston DA. Symptomatic Epstein-Barr virus infection and multiple sclerosis. J Neurol Neurosurg Psychiatry 1993;56:167-8.
132. Riggs JE. Cigarette smoking and Parkinson disease: the illusion of a neuroprotective effect. Clin Neuropharmacol 1992;15:88-99.
133. Ben-Shlomo Y. Smoking and neurodegenerative diseases. Lancet 1993;342:1239.
134. Yong VW, Perry TL. Monoamine oxidase B, smoking and Parkinson's disease. J Neurol Sci 1986;72:265-72.
135. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994;344:796-8.
136. Smith PR, Copper JM, Govan GG, Harding AE, Schapira AHV. Smoking and mitochondrial function: a model for environmental toxins. Q J Med 1993;86:657-60.
137. Gresham LS, Molgaard CA, Smith RA. Induction of cytochrome P-450 enzymes via tobacco smoke: a potential mechanism for developing resistance to environmental toxins as related to parkinsonism and other neurologic diseases. Neuroepidemiology 1993;12:114-6.
138. Golbe LJ, Cody RA, Duvoisin RC. Smoking and Parkinson's disease: search for a dose-response relationship. Arch Neurol 1986;43:774-80.
139. Eysenck HJ, Tarrant M, Woolf M, England L. Smoking and personality. BMJ 1960;i:456-60.
140. Forgays DG, Bonaiuto P, Wrzesniewski K, Forgays DK. Personality and cigarette smoking in Italy, Poland and the United States. Int J Addict 1993;28:399-413.
141. Plassman BL, Helms MJ, Welsh KA, Saunders AM, Breitner JCS. Smoking, Alzheimer' disease and confounding with genes. Lancet 1995;345:387.
142. Godwin Austen RB, Lee PN, Marmot MG, Stern GM. Smoking and Parkinson's disease. J Neurol Neurosurg Psychiatry 1982;45:577-81.
143. Raphael K. Recall bias: a proposal for assessment and control. Int J Epidemiol 1987;16:167-70.
144. Weiss N. Should we consider a subject's knowledge of the etiologic hypothesis in the analysis of case-control studies? Am J Epidemiol 1994;139:247-9.
145. Rajput AH, Utti RJ, Stern W, Laverry W. Early onset Parkinson's disease in Saskatchewan - environmental considerations for etiology. Can J Neurol Sci 1986;13: 312-6.
146. Martyn CN. Choosing cases and controls in neurological research. J Neurol Neurosurg Psychiatry 1990;53:453-4.
147. Blazer DG, Landerman LR, Fillenbaum G, Horner R. Health services access and use among older adults in North Carolina: urban vs rural residents. Am J Public Health 1995;85:1384-90.
148. Rybicki BA, Johnson CC, Gorell JM. Demographic differences in referral rates to neurologists of patients with suspected Parkinson's disease: implications for case-control study design. Neuroepidemiology 1995;14:72-81.
149. Schlesselman JJ. Case-control studies: design, conduct, analysis. New York: Oxford University Press, 1982:1-354.
150. Granieri E, Carreras M, Casetta I, et al. Parkinson's disease in Ferrara, Italy, 1967 through 1987. Arch Neurol 1991;49:854-7.
151. Phillips AN, Davey Smith G. How independent are "independent" effects? Relative risk estimation when correlated exposures are measured imprecisely. J Clin Epidemiol 1991;44:1223-31.
152. Rajput AH, Uitti RJ, Stern W, et al. Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson's disease. Can J Neurol Sci 1987;14:414-8.
153. Spencer P. Guam ALS/Parkinsonism-dementia: a long-latency neurotoxic disorder caused by "slow toxin(s)" in food? Can J Neurol Sci 1987;14:347-57.
154. Willett W. Overview of nutritional epidemiology. In: Willett W, ed. Nutritional epidemiology. New York: Oxford University Press, 1990;3-19.
155. Dwyer JT, Gardner J, Halvorsen K, Krall EA, Cohen A, Valadian I. Memory of food intake in the distant past. Am J Epidemiol 1989;130:1033-46.
156. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-83.
157. Marttila RJ, Rinne UK. Arteriosclerosis, heredity, and some previous infections in the etiology of Parkinson's disease. A case-control study. Clin Neurol Neurosurg 1976;79:46-56.
158. Hoehn MMM. Parkinson's disease: progression and mortality. Adv Neurol 1986;45:457-61.
159. Marmot MG. Mortality and Parkinson's disease. In: Rose FC, Capildeo R, eds. Research progress in Parkinson's disease. London: Pitman, 1988;9-16.
160. Rajput AH, Offord KP, Beard CM, Kurland LT. A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease. Neurology 1987; 37:226-32.
161. Di Monte D, Sandy MS, Blank L, Smith MT. Fructose prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced ATP depletion and toxicity in isolated hepatocytes. Biochem Biophys Res Commun 1988;153: 734-40.
162. Möller H, Mellemkjaer L, McLaughlin JK, Olsen JH. Occurence of different cancers in patients with Parkinson's disease. BMJ 1995;310:1500-1.
163. Barbeau A, Joly JG. Parkinson et cancer. Union Med Can 1963;92:169-74.
164. Jansson B, Jankovic J. Low cancer rates among patients with Parkinson's disease. Ann Neurol 1985;17:505-9.
165. Barrett-Connor E. Are we living longer or dying longer? In: Poulter N, Sever P, Thom S, eds. Cardiovascular disease: risk factors and intervention. Oxford: Raddiffe Medical Press, 1993:89-99.